Pre-Approval Deals in Korean Pharmaceutical Industry: A Strategic Advantage
Key Takeaways
Pre-approval deals in the Korean pharmaceutical and biotechnology sectors are becoming increasingly common. These agreements are made before global regulatory approvals, indicating strong confidence in the data and technological capabilities of Korean-developed drugs. Such deals are not only a testament to the competitiveness of these drugs but also serve as a strategic move to secure market share and mitigate financial risks.
Background
In recent years, several Korean pharmaceutical companies have entered into licensing agreements with global partners before obtaining regulatory approvals. Notable examples include Hanmi Pharmaceutical's deal with Sanfer for "Efpeglenatide," Medipost's agreement with Teikoku Pharmaceutical for "Cartistem," and SK Biopharm's partnership with Arvelle Therapeutics for "Xcopri." These deals often involve significant non-refundable upfront payments, reflecting the global partners' confidence in the drugs' mechanisms and data.
What This Means in Practice
From a legal and operational standpoint, pre-approval deals offer several advantages. They allow companies to share the financial burden of late-stage clinical trials and provide a financial cushion through upfront payments. These agreements also enable companies to leverage the local distribution networks of their partners, facilitating rapid market entry upon approval. Furthermore, the rigorous due diligence conducted by partner companies before entering these agreements serves as an unofficial validation of the drug's efficacy and safety, enhancing its credibility in the global market.
Recommended Next Steps
Pharmaceutical companies considering pre-approval deals should focus on building robust data packages and demonstrating clear mechanisms of action for their drugs. Engaging in thorough due diligence and establishing strong partnerships with reputable global companies can enhance the likelihood of successful agreements. Additionally, companies should prepare for the operational demands of rapid market entry, including scaling production and distribution capabilities to meet anticipated demand.